| Medical and Health Sciences | Lifetime | 12 | US 6 | 100.00 |
| Economics and Finance | Lifetime | 928 | US 509 | 99.42 |
| Medical and Health Sciences | 2021-2025 | 38 | US 20 | 99.99 |
| Economics and Finance | 2021-2025 | 503 | US 120 | 98.16 |
| Cardiology and Cardiovascular Medicine | Lifetime | 4 | US 2 | 100.00 |
| Epidemiology | Lifetime | 94 | US 47 | 99.86 |
| Surgery | Lifetime | 329 | US 183 | 99.72 |
| Econometrics and Quantitative Economics | Lifetime | 519 | US 307 | 99.49 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 251 | US 140 | 99.25 |
| Emergency Medicine | Lifetime | 128 | US 68 | 98.99 |
| Complementary and Alternative Medicine | Lifetime | 233 | US 92 | 98.88 |
| Pulmonary and Respiratory Medicine | Lifetime | 722 | US 380 | 98.92 |
| Geriatrics and Gerontology | Lifetime | 80 | US 41 | 98.11 |
| Family Practice | Lifetime | 45 | US 26 | 97.42 |
| Rehabilitation | Lifetime | 221 | US 87 | 97.42 |
| Internal Medicine | Lifetime | 239 | US 101 | 94.71 |
| Nephrology | Lifetime | 507 | US 242 | 94.67 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 8 | US 5 | 99.96 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 41 | US 27 | 99.53 |
| Epidemiology | 2021-2025 | 141 | US 43 | 99.09 |
| Econometrics and Quantitative Economics | 2021-2025 | 356 | US 63 | 98.20 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 412 | US 132 | 95.68 |
| General Health Professions | 2021-2025 | 697 | US 241 | 94.46 |
| Surgery | 2021-2025 | 753 | US 287 | 93.38 |
| Emergency Medicine | 2021-2025 | 239 | US 107 | 85.11 |
| Clinical Neurology | 2021-2025 | 445 | US 171 | 84.20 |
| Family Practice | 2021-2025 | 45 | US 14 | 82.66 |
| Cardiovascular Function and Risk Factors | Lifetime | 2 | US 2 | 99.99 |
| Heart Failure Treatment and Management | Lifetime | 2 | US 2 | 99.99 |
| Cardiac pacing and defibrillation studies | Lifetime | 3 | US 3 | 99.97 |
| Medication Adherence and Compliance | Lifetime | 1 | US 1 | 99.89 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 4 | US 4 | 99.77 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 23 | US 14 | 99.87 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 21 | US 8 | 99.90 |
| Potassium and Related Disorders | Lifetime | 2 | US 2 | 99.96 |
| Stroke Rehabilitation and Recovery | Lifetime | 12 | US 5 | 99.88 |
| Acute Ischemic Stroke Management | Lifetime | 20 | US 8 | 99.89 |
| Mechanical Circulatory Support Devices | Lifetime | 25 | US 15 | 99.78 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 50 | US 21 | 99.78 |
| Cardiac Health and Mental Health | Lifetime | 19 | US 12 | 99.66 |
| Diabetes Treatment and Management | Lifetime | 40 | US 22 | 99.78 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 69 | US 31 | 99.78 |
| Acute Myocardial Infarction Research | Lifetime | 50 | US 30 | 99.82 |
| Chronic Disease Management Strategies | Lifetime | 37 | US 16 | 99.40 |
| Lipoproteins and Cardiovascular Health | Lifetime | 65 | US 39 | 99.62 |
| Cardiac Arrest and Resuscitation | Lifetime | 115 | US 62 | 99.53 |
| Emergency and Acute Care Studies | Lifetime | 84 | US 46 | 99.21 |
| Blood Pressure and Hypertension Studies | Lifetime | 128 | US 57 | 99.50 |
| Cardiac Arrhythmias and Treatments | Lifetime | 166 | US 90 | 99.48 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 105 | US 44 | 99.45 |
| Clinical practice guidelines implementation | Lifetime | 77 | US 25 | 98.77 |
| Cardiac Structural Anomalies and Repair | Lifetime | 229 | US 155 | 99.25 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 331 | US 180 | 99.04 |
| Transplantation: Methods and Outcomes | Lifetime | 180 | US 112 | 98.78 |
| Healthcare Policy and Management | Lifetime | 225 | US 169 | 98.64 |
| Cardiovascular and exercise physiology | Lifetime | 247 | US 97 | 98.81 |
| COVID-19 and healthcare impacts | Lifetime | 254 | US 99 | 96.37 |
| Cardiac Imaging and Diagnostics | Lifetime | 848 | US 421 | 98.74 |
| Electrolyte and hormonal disorders | Lifetime | 198 | US 98 | 97.89 |
| Heart Rate Variability and Autonomic Control | Lifetime | 566 | US 266 | 98.20 |
| Pharmaceutical Economics and Policy | Lifetime | 160 | US 91 | 97.50 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 632 | US 276 | 98.39 |
| Dialysis and Renal Disease Management | Lifetime | 377 | US 152 | 98.24 |
| Cardiovascular Issues in Pregnancy | Lifetime | 307 | US 129 | 97.35 |
| Erythropoietin and Anemia Treatment | Lifetime | 156 | US 68 | 97.29 |
| Cardiovascular Health and Risk Factors | Lifetime | 229 | US 137 | 96.92 |
| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 398 | US 170 | 97.13 |
| Peripheral Artery Disease Management | Lifetime | 796 | US 430 | 96.04 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 498 | US 227 | 95.69 |
| Primary Care and Health Outcomes | Lifetime | 990 | US 566 | 95.48 |
| Heart rate and cardiovascular health | Lifetime | 80 | US 31 | 94.52 |
| Hospital Admissions and Outcomes | Lifetime | 210 | US 155 | 92.97 |
| Healthcare cost, quality, practices | Lifetime | 659 | US 364 | 92.92 |
| Pharmacy and Medical Practices | Lifetime | 331 | US 99 | 89.08 |
| Machine Learning in Healthcare | Lifetime | 531 | US 270 | 88.88 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 325 | US 78 | 82.54 |
| Sex and Gender in Healthcare | Lifetime | 770 | US 398 | 72.39 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 16 | US 9 | 99.88 |
| Heart Failure Treatment and Management | 2021-2025 | 10 | US 7 | 99.90 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 14 | US 5 | 99.76 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 44 | US 12 | 99.16 |
| Diabetes Treatment and Management | 2021-2025 | 37 | US 25 | 99.64 |
| Potassium and Related Disorders | 2021-2025 | 6 | US 4 | 99.41 |
| Cardiac Health and Mental Health | 2021-2025 | 26 | US 12 | 98.21 |
| Acute Ischemic Stroke Management | 2021-2025 | 84 | US 28 | 99.20 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 93 | US 38 | 98.82 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 170 | US 51 | 98.61 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 58 | US 7 | 97.19 |
| Acute Myocardial Infarction Research | 2021-2025 | 177 | US 51 | 97.44 |
| Mechanical Circulatory Support Devices | 2021-2025 | 198 | US 96 | 97.01 |
| COVID-19 and healthcare impacts | 2021-2025 | 359 | US 125 | 94.18 |
| Stroke Rehabilitation and Recovery | 2021-2025 | 251 | US 61 | 96.16 |
| Healthcare Policy and Management | 2021-2025 | 141 | US 113 | 94.97 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 283 | US 111 | 95.46 |
| Chronic Disease Management Strategies | 2021-2025 | 237 | US 45 | 93.35 |
| Cardiac Arrest and Resuscitation | 2021-2025 | 700 | US 254 | 93.81 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 380 | US 77 | 91.93 |
| Medication Adherence and Compliance | 2021-2025 | 174 | US 67 | 89.43 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 496 | US 131 | 87.24 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 891 | US 237 | 90.02 |
| Electrolyte and hormonal disorders | 2021-2025 | 181 | US 56 | 85.63 |
| Pancreatic function and diabetes | 2021-2025 | 941 | US 309 | 87.16 |
| Dialysis and Renal Disease Management | 2021-2025 | 818 | US 184 | 87.77 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 962 | US 254 | 82.71 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 685 | US 212 | 70.44 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 580 | US 151 | 62.54 |
| Pharmaceutical industry and healthcare | 2021-2025 | 714 | US 389 | 23.89 |